Back to News
Market Impact: 0.2
Krystal's Q3 Profit Declines As Clinical Portfolio Advances; Stock Dips By Over 12%
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Krystal Biotech reported lower profit for the third quarter as increased income tax expenses offset high revenues. The article provides no profit, revenue, or tax figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
KRYS-0.25
More News
- Stocks making the biggest moves midday: Oracle, SpaceX, Tempus AI, Rivian & more
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash